{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:31:11Z","timestamp":1789000271047,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oxygen-induced retinopathy (OIR) upregulates M\u00fcller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of M\u00fcller cell-VEGFA with short-hairpin RNAs to VEGFA or VEGF<jats:sub>164<\/jats:sub> via subretinal lentivirus delivery (L-VEGFAshRNA, L-VEGF164shRNA) on retinal structure and function in a rat OIR model. Lectin-stained retinal flat mounts analyzed for areas of avascular\/total retina (AVA) and intravitreal neovascular\/total retina (IVNV) showed initial significantly reduced IVNV by L-VEGFAshRNA and L-VEGF164shRNA compared to control, luciferase-shRNA lentivirus, without late recurrence. Spectral-domain optical coherence tomography (OCT) and immunohistochemical sections (IHC) demonstrated changes in retinal layer thicknesses in L-VEGFAshRNA\u00a0or L-VEGF164shRNA \u00a0compared to control. Ganzfeld electroretinograms were increased in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Erythropoietin (EPO), brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, neurotrophin-3 (NT-3) mRNAs were increased in L-VEGFAshRNA, but not L-VEGF164shRNA retinas. In cultured rat M\u00fcller cells, knockdown of VEGF upregulated NT-3 and EPO, whereas treatment with EPO activated neuroprotective signaling. Methods to reduce IVNV by selective knockdown of VEGFA, and particularly VEGF<jats:sub>164<\/jats:sub>, in M\u00fcller cells may have fewer deleterious effects than nonselective VEGFA inhibition to all cells in the retina.<\/jats:p>","DOI":"10.1038\/s41598-018-20278-4","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T14:14:46Z","timestamp":1516889686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Targeted Knockdown of Overexpressed VEGFA or VEGF164 in M\u00fcller cells maintains retinal function by triggering different signaling mechanisms"],"prefix":"10.1038","volume":"8","author":[{"given":"Silke","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thipparat","family":"Suwanmanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Stoddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Kafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elizabeth","family":"Hartnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"20278_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/archdischild-2016-310532","volume":"102","author":"AL Solebo","year":"2017","unstructured":"Solebo, A. L., Teoh, L. & Rahi, J. Epidemiology of blindness in children. Arch Dis Child 102, 853\u2013857, https:\/\/doi.org\/10.1136\/archdischild-2016-310532 (2017).","journal-title":"Arch Dis Child"},{"key":"20278_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3928\/23258160-20170630-06","volume":"48","author":"CA Ludwig","year":"2017","unstructured":"Ludwig, C. A., Chen, T. A., Hernandez-Boussard, T., Moshfeghi, A. A. & Moshfeghi, D. M. The Epidemiology of Retinopathy of Prematurity in the United States. Ophthalmic surgery, lasers & imaging retina 48, 553\u2013562, https:\/\/doi.org\/10.3928\/23258160-20170630-06 (2017).","journal-title":"Ophthalmic surgery, lasers & imaging retina"},{"key":"20278_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","volume":"62","author":"ME Hartnett","year":"2017","unstructured":"Hartnett, M. E. Advances in understanding and management of retinopathy of prematurity. Surv Ophthalmol 62, 257\u2013276, https:\/\/doi.org\/10.1016\/j.survophthal.2016.12.004 (2017).","journal-title":"Surv Ophthalmol"},{"key":"20278_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner, H. A., Kennedy, K. A. & Chuang, A. Z. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364, 603\u2013615, https:\/\/doi.org\/10.1056\/NEJMoa1007374 (2011).","journal-title":"N Engl J Med"},{"key":"20278_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","volume":"27","author":"JS Penn","year":"2008","unstructured":"Penn, J. S. et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27, 331\u2013371, https:\/\/doi.org\/10.1016\/j.preteyeres.2008.05.001 (2008).","journal-title":"Prog Retin Eye Res"},{"key":"20278_CR6","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","volume":"15","author":"J Stone","year":"1995","unstructured":"Stone, J. et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. Journal of Neuroscience 15, 4738\u20134747 (1995).","journal-title":"Journal of Neuroscience"},{"key":"20278_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"WC Wu","year":"2017","unstructured":"Wu, W. C. et al. Serum Vascular Endothelial Growth Factor after Bevacizumab or Ranibizumab Treatment for Retinopathy of Prematurity. Retina 37, 694\u2013701, https:\/\/doi.org\/10.1097\/IAE.0000000000001209 (2017).","journal-title":"Retina"},{"key":"20278_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/org.4.4.7415","volume":"4","author":"JJ Haigh","year":"2008","unstructured":"Haigh, J. J. Role of VEGF in organogenesis. Organogenesis 4, 247\u2013256 (2008).","journal-title":"Organogenesis"},{"key":"20278_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3928\/23258160-20170301-10","volume":"48","author":"AR Hajrasouliha","year":"2017","unstructured":"Hajrasouliha, A. R., Garcia-Gonzales, J. M., Shapiro, M. J., Yoon, H. & Blair, M. P. Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab. Ophthalmic Surg Lasers Imaging Retina 48, 255\u2013259, https:\/\/doi.org\/10.3928\/23258160-20170301-10 (2017).","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"20278_CR10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","volume":"135","author":"DK Wallace","year":"2017","unstructured":"Wallace, D. K. et al. Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA ophthalmology 135, 654\u2013656, https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1055 (2017).","journal-title":"JAMA ophthalmology"},{"key":"20278_CR11","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1167\/iovs.13-11625","volume":"54","author":"M McCloskey","year":"2013","unstructured":"McCloskey, M. et al. Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 54, 2020\u20132026, https:\/\/doi.org\/10.1167\/iovs.13-11625 (2013).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"20278_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1167\/iovs.13-13429","volume":"55","author":"H Wang","year":"2014","unstructured":"Wang, H. et al. Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 55, 737\u2013744, https:\/\/doi.org\/10.1167\/iovs.13-13429 (2014).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"20278_CR13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.ajpath.2013.05.011","volume":"183","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. Short hairpin RNA-mediated knockdown of VEGFA in Muller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity. The American journal of pathology 183, 964\u2013974, https:\/\/doi.org\/10.1016\/j.ajpath.2013.05.011 (2013).","journal-title":"The American journal of pathology"},{"key":"20278_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1167\/iovs.13-13755","volume":"55","author":"Y Jiang","year":"2014","unstructured":"Jiang, Y. et al. Targeting Muller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 55, 824\u2013831, https:\/\/doi.org\/10.1167\/iovs.13-13755 (2014).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"20278_CR15","first-page":"512","volume":"10","author":"JR McColm","year":"2004","unstructured":"McColm, J. R., Geisen, P. & Hartnett, M. E. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis 10, 512\u2013520 (2004).","journal-title":"Mol Vis"},{"key":"20278_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1084\/jem.20022027","volume":"198","author":"S Ishida","year":"2003","unstructured":"Ishida, S. et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198, 483\u2013489, https:\/\/doi.org\/10.1084\/jem.20022027 (2003).","journal-title":"J Exp Med"},{"key":"20278_CR17","doi-asserted-by":"publisher","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","volume":"3","author":"M Saint-Geniez","year":"2008","unstructured":"Saint-Geniez, M. et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 3, e3554, https:\/\/doi.org\/10.1371\/journal.pone.0003554 (2008).","journal-title":"PLoS One"},{"key":"20278_CR18","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.ajpath.2014.02.016","volume":"184","author":"HY Park","year":"2014","unstructured":"Park, H. Y., Kim, J. H. & Park, C. K. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. The American journal of pathology 184, 1752\u20131762, https:\/\/doi.org\/10.1016\/j.ajpath.2014.02.016 (2014).","journal-title":"The American journal of pathology"},{"key":"20278_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ajpath.2011.11.031","volume":"180","author":"H Wang","year":"2012","unstructured":"Wang, H. et al. VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. The American journal of pathology 180, 1243\u20131253, https:\/\/doi.org\/10.1016\/j.ajpath.2011.11.031 (2012).","journal-title":"The American journal of pathology"},{"key":"20278_CR20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/eye.2016.94","volume":"30","author":"SL Shirley Ding","year":"2016","unstructured":"Shirley Ding, S. L. et al. Revisiting the role of erythropoietin for treatment of ocular disorders. Eye (London, England) 30, 1293\u20131309, https:\/\/doi.org\/10.1038\/eye.2016.94 (2016).","journal-title":"Eye (London, England)"},{"key":"20278_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. The American journal of pathology 171, 53\u201367, https:\/\/doi.org\/10.2353\/ajpath.2007.061237 (2007).","journal-title":"The American journal of pathology"},{"key":"20278_CR22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1001\/jamaophthalmol.2017.2195","volume":"135","author":"ME Hartnett","year":"2017","unstructured":"Hartnett, M. E. Electroretinographic Responses in the Smallest Eyes. JAMA Ophthalmol 135, 862\u2013863, https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.2195 (2017).","journal-title":"JAMA Ophthalmol"},{"key":"20278_CR23","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/jamaophthalmol.2017.2069","volume":"135","author":"AEC Molnar","year":"2017","unstructured":"Molnar, A. E. C., Andreasson, S. O., Larsson, E. K. B., Akerblom, H. M. & Holmstrom, G. E. Reduction of Rod and Cone Function in 6.5-Year-Old Children Born Extremely Preterm. JAMA ophthalmology 135, 854\u2013861, https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.2069 (2017).","journal-title":"JAMA ophthalmology"},{"key":"20278_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu, J. et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130, 1000\u20131006, https:\/\/doi.org\/10.1001\/archophthalmol.2012.592 (2012).","journal-title":"Arch Ophthalmol"},{"key":"20278_CR25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/path.2611","volume":"219","author":"Y Bai","year":"2009","unstructured":"Bai, Y. et al. M++ ller cell-derived VEGF is a significant contributor to retinal neovascularization. The Journal of Pathology 219, 446\u2013454 (2009).","journal-title":"The Journal of Pathology"},{"key":"20278_CR26","unstructured":"al, B. S. e. Effect of subregional injection on retinal structure and function in a rat oxygen-induced retinopathy model. Molecular Vision 23 (2017)."},{"key":"20278_CR27","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.ajpath.2011.12.033","volume":"180","author":"FM Mowat","year":"2012","unstructured":"Mowat, F. M. et al. Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy. The American journal of pathology 180, 1726\u20131739, https:\/\/doi.org\/10.1016\/j.ajpath.2011.12.033 (2012).","journal-title":"The American journal of pathology"},{"key":"20278_CR28","first-page":"437","volume":"13","author":"CS von Bartheld","year":"1998","unstructured":"von Bartheld, C. S. Neurotrophins in the developing and regenerating visual system. Histology and histopathology 13, 437\u2013459 (1998).","journal-title":"Histology and histopathology"},{"key":"20278_CR29","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas, E. S. et al. Pegaptanib for neovascular age-related macular degeneration. The New England Journal of Medicine 351, 2805\u20132816 (2004).","journal-title":"The New England Journal of Medicine"},{"key":"20278_CR30","first-page":"1541","volume":"3","author":"LM Hu","year":"2011","unstructured":"Hu, L. M. et al. EPO reduces reactive gliosis and stimulates neurotrophin expression in Muller cells. Front Biosci (Elite Ed) 3, 1541\u20131555 (2011).","journal-title":"Front Biosci (Elite Ed)"},{"key":"20278_CR31","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1007\/s12035-015-9438-1","volume":"53","author":"Z Jia","year":"2016","unstructured":"Jia, Z. et al. Erythropoietin Attenuates the Memory Deficits in Aging Rats by Rescuing the Oxidative Stress and Inflammation and Promoting BDNF Releasing. Molecular neurobiology 53, 5664\u20135670, https:\/\/doi.org\/10.1007\/s12035-015-9438-1 (2016).","journal-title":"Molecular neurobiology"},{"key":"20278_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-8-51","volume":"8","author":"AS Cockrell","year":"2011","unstructured":"Cockrell, A. S., van Praag, H., Santistevan, N., Ma, H. & Kafri, T. The HIV-1 Rev\/RRE system is required for HIV-1 5\u2019 UTR cis elements to augment encapsidation of heterologous RNA into HIV-1 viral particles. Retrovirology 8, 51, https:\/\/doi.org\/10.1186\/1742-4690-8-51 (2011).","journal-title":"Retrovirology"},{"key":"20278_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0014-4835(90)90063-Z","volume":"51","author":"D Hicks","year":"1990","unstructured":"Hicks, D. & Courtois, Y. The growth and behaviour of rat retinal Muller cells in vitro. 1. An improved method for isolation and culture. Exp Eye Res 51, 119\u2013129 (1990).","journal-title":"Exp Eye Res"},{"key":"20278_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/sj.jp.7210842","volume":"23","author":"AF Robertson","year":"2003","unstructured":"Robertson, A. F. Reflections on errors in neonatology: I. The \u201cHands-Off\u201d years, 1920 to 1950. J Perinatol 23, 48\u201355, https:\/\/doi.org\/10.1038\/sj.jp.7210842 (2003).","journal-title":"J Perinatol"},{"key":"20278_CR35","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3109\/02713689609017637","volume":"15","author":"KA Roberto","year":"1996","unstructured":"Roberto, K. A., Tolman, B. L. & Penn, J. S. Long-term retinal vascular abnormalities in an animal model of retinopathy of prematurity. Curr Eye Res 15, 932\u2013937 (1996).","journal-title":"Curr Eye Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20278-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:47:59Z","timestamp":1671587279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20278-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["20278"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-20278-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"29 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2003"}}